Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape the future of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in Personalized Medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to Personalized Medicine are subject to rigorous peer review. Topics addressed include: Advances in molecular diagnostics; Biochip/microarray technologies; Biological therapies or vaccine approaches at specific genetic and immunologic targets; Cost-benefit issues for personalized medicine; Ethics in personalized medicine; Impact of personalized medicine on healthcare and the pharmaceutical industry; Impact of the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics and pharmacoproteomics; Incorporation of genetic analysis in clinical trials methodology; Integration of diagnosis with therapy; Prediction of adverse reactions of drugs and drug safety; Treatment monitoring.